Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients
Plain-language summary
This trial is testing Go-CHOP (Golidocitinib plus Cyclophosphamide for patients with enteropathy-associated T-cell lymphoma who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Newly diagnosed, not yet treated
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone) (DRUG): Induction Treatment: Golidocitinib:150mg QD Cyclophosphamide:750mg/m2，d1 vincristine:1.4mg/m2，d1(max 2mg) doxorubicin:50mg/m2，d1 Prednisone:60mg/m2 (max 100mg)，d1-d5 Every 21 days | Golidocitinib (DRUG): Maintenance Treatment: Complete remission patients will further divide into two groups. Unfit, frail old patients will receieve Golidocitinib 150mg QD for two years. Fit, young patients will receive ASCT.
Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone), Golidocitinib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details